Neuralgia News and Research

RSS

Neuralgia is pain in one or more nerves that occurs without stimulation of pain receptor (nociceptor) cells. Neuralgia pain is produced by a change in neurological structure or function rather than by the excitation of pain receptors that causes nociceptive pain.

American Shared Hospital Services third quarter revenue increases to $9,148,000

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced financial results for the third quarter and first nine months of 2011.

14 Nov 2011

AMS pleased with CMS' increase in 2012 payment rate for proton therapy

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, said today that the recent announcement by the Centers for Medicare & Medicade Services (CMS) of a 15% increase in the payment rate of proton therapy for hospital based centers beginning in 2012 strengthens the economic case for the proton centers now under development by the Company.

7 Nov 2011

Inhibitex third quarter revenue increases to $1.3 million

Inhibitex, Inc. today announced its financial results for the third quarter ended September 30, 2011 and provided an update on several recent corporate developments, including top-line safety and antiviral data from the first cohort in its ongoing clinical trial designed to evaluate higher doses of INX-189, an oral nucleotide polymerase inhibitor, being developed to treat chronic infections caused by hepatitis C virus (HCV), administered as monotherapy or in combination with ribavirin for seven days.

4 Nov 2011

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE (bortezomib) for Injection, which updates the label to include additional long-term overall survival (OS) data from the VISTA trial.

2 Nov 2011

DARA BioSciences' KRN5500 reduces neuropathic pain in patients with cancer

DARA BioSciences, Inc. today announced the Journal of Pain and Symptom Management, an internationally respected, peer-reviewed journal, has published results of a Phase II safety and efficacy study of KRN5500 for the treatment of neuropathic pain in patients with cancer.

11 Oct 2011

Laser Med Center receives FDA approval for device to treat Trigeminal Neuralgia

Laser Med Center, which specializes in treating Trigeminal Neuralgia, has received an FDA approval for its revolutionary laser device. This is a non-invasive alternative to surgery, which treats pain through nerve tissue regeneration.

19 Sep 2011

Aestus to develop ATx09-002 for treatment of neuropathic pain

Aestus Therapeutics, Inc. and Prosidion Ltd., a wholly owned subsidiary of Astellas Pharma Inc., announced today a license agreement providing Aestus with exclusive, world-wide rights to the Prosidion investigational product PSN-357.

19 Sep 2011

Spinifex initiates EMA401 Phase 2 trial in postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced the first patients have been treated in its Phase 2 clinical trial of EMA401 in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.

19 Sep 2011

Microvascular compression syndrome may cause Parkinson's

A potentially treatable blood vessel abnormality in the brain may be the cause of Parkinson's Disease in some patients, according to a study published today in the journal Neurology International by a team of leading physicians and neuroscientists at Pittsburgh's Allegheny General Hospital.

8 Sep 2011

Spinifex secures AU$6.25 million in expanded Series B funding

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured a further AU$6.25 million of venture capital investment from GBS Venture Partners Limited, Brandon Capital Partners Pty Limited, Uniseed Management Pty Limited and UniQuest Pty Limited to fund the development of its pain management drug, EMA401.

23 Aug 2011

Santarus, Depomed enter new commercialization agreement for GLUMETZA

Santarus, Inc. and Depomed, Inc. today announced that they have entered into a new commercialization agreement for GLUMETZA (metformin hydrochloride extended release tablets) under which Santarus will assume broad commercial, manufacturing and regulatory responsibilities to replace a promotion agreement that the companies entered into in July 2008.

23 Aug 2011

American Shared Hospital Services first half 2011 revenues increase 4.0% to $8,573,000

8 Aug 2011

Inhibitex second quarter net loss decreases to $5.3 million

Inhibitex, Inc. today announced its financial results for the second quarter ended June 30, 2011 and provided an update on several recent clinical and corporate developments.

8 Aug 2011

Vampire bats can smell blood-rich prey: Study

In the labs of University of California, San Francisco and from the wilds of Venezuela scientists have discovered how vampire bats have evolved over the years with a unique weapon that enables them to zero in for a ravenous feed on the warmest blood vessels of their prey.

4 Aug 2011

Ironwood licenses worldwide rights to Depomed's Acuform drug delivery technology

Ironwood Pharmaceuticals, Inc. and Depomed, Inc. today announced that Ironwood has licensed worldwide rights to utilize Depomed's Acuform gastric retentive drug delivery technology for an Ironwood early stage development program, continuing Ironwood's efforts to augment its development pipeline beyond linaclotide.

28 Jul 2011

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the submission of a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration for VELCADE® (bortezomib) for injection to add overall survival data after a five-year follow up to the product label.

20 Jul 2011

Enrollment complete in NeurogesX NGX-1998 Phase 2 clinical study for postherpetic neuralgia

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced the completion of patient enrollment in its Phase 2 clinical study of NGX-1998, a topical liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN).

16 Jun 2011

Skin cell-derived CGRP-beta may cause chronic pain

A new study may explain why only 50% of patients experiencing chronic nerve pain achieve even partial relief from existing therapeutics. The study, published in the June 6 online version of the international research journal PAIN, reveals that certain types of chronic pain may be caused by signals from the skin itself, rather than damage to nerves within the skin, as previously thought.

9 Jun 2011

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two studies of VELCADE (bortezomib) for Injection based combinations in patients with relapsed or refractory multiple myeloma (MM).

8 Jun 2011

Millennium presents VELCADE Phase III trial data in multiple myeloma at IMW meeting

Millennium: The Takeda Oncology Company today reported the presentation of results of a randomized Phase III trial that investigated the effect of consolidation with single-agent VELCADE for Injection in newly diagnosed multiple myeloma patients after autologous stem cell transplant.

7 May 2011

Neuralgia News and Research

Further Reading

American Shared Hospital Services third quarter revenue increases to $9,148,000

AMS pleased with CMS' increase in 2012 payment rate for proton therapy

Inhibitex third quarter revenue increases to $1.3 million

Takeda receives FDA approval for VELCADE sNDA to treat MM

DARA BioSciences' KRN5500 reduces neuropathic pain in patients with cancer

Laser Med Center receives FDA approval for device to treat Trigeminal Neuralgia

Aestus to develop ATx09-002 for treatment of neuropathic pain

Spinifex initiates EMA401 Phase 2 trial in postherpetic neuralgia

Microvascular compression syndrome may cause Parkinson's

Spinifex secures AU$6.25 million in expanded Series B funding

Santarus, Depomed enter new commercialization agreement for GLUMETZA

American Shared Hospital Services first half 2011 revenues increase 4.0% to $8,573,000

Inhibitex second quarter net loss decreases to $5.3 million

Vampire bats can smell blood-rich prey: Study

Ironwood licenses worldwide rights to Depomed's Acuform drug delivery technology

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

Enrollment complete in NeurogesX NGX-1998 Phase 2 clinical study for postherpetic neuralgia

Skin cell-derived CGRP-beta may cause chronic pain

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Millennium presents VELCADE Phase III trial data in multiple myeloma at IMW meeting

Exploring the intersection of biology and proteomics

Unlocking the Secrets of Multiple Sclerosis Progression: Brain-Immune Cell Communication

Passing on Polycystic Ovary Syndrome: Health risks for male offspring of women with PCOS

Latest News